<DOC>
	<DOCNO>NCT02723071</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics , anti-tumor efficacy ocrelizumab participant progressive follicular NHL .</brief_summary>
	<brief_title>A Study Ocrelizumab Participants With Follicular Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<criteria>Follicular NHL Documented history response , stable disease 6 month duration , rituximabcontaining regimen last treatment enrollment study No evidence hepatitis B C Prior monoclonal antibody therapy rituximab , anticancer vaccine , radioimmunotherapy cancer History severe allergic anaphylactic reaction humanize murine monoclonal antibody , know sensitivity allergy murine product Major nondiagnostic surgery within 4 week Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>